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Highlights 
 The vaccine consists of four major sections: toll-like receptor 4 adjuvant, 
toll-like receptor 5 adjuvant and two epitopes. 
 Each section was joined together by appropriate linkers. 
 Different strategies were applied to enhance immunogenicity of peptide 
vaccine. 
 The vaccine is able to protection of population on all members of α-
papillomaviridea family. 
 The vaccine has a high quality structure, appropriate physicochemical 




Background: Oncogenic human papilloma viruses (HPV) are the cause of various types 
of cancer, specifically cervical cancer. L1 protein is the main protein of HPV capsid 











coverage on the various high risk HPV types. Therefore, having a low cost potent HPV 
vaccine to protect against all members of the α-papillomaviridea family will be 
promising. In this study, L1 protein-based peptide vaccine was designed using 
immunoinformatics methods which provides physicochemical properties such as stability 
in room temperature, potential of antigenicity, non-allergic properties and no requirement 
with eukaryotic host system. 
Results: The designed vaccine has two HPV conserved epitopes with lengths 18 and 27 
amino acids in all members of α-papillomaviridea. These peptides promote humoral and 
cellular immunity and INF-γ responses. In order to ensure strong induction of immune 
responses, Flagellin, a Toll like receptor 5(TLR-5) agonist, and a short synthetic toll like 
receptor 4 (TLR-4) agonist were also joined to the epitopes. Structure of the designed- 
vaccine was validated using Rampage and ERRAT and a high quality 3D structure of the 
vaccine protein was provided. Docking studies demonstrated an appropriate and stable 
interaction between the vaccine and TLR-5. 
Conclusions: The vaccine is expected to have a high quality structure and suitable 
properties including high stability, solubility and a high potential to be expressed in 
E.coli. High potentiality of the vaccine in inducing humoral and cellular immune 
responses, may be considered as an anti-tumor vaccine. 
Keywords: Conserved epitopes; Vaccine, HPV, Adjuvant; Immunoinformatics;Tertiary 














Cervical cancer (CC) is the fourth common cancer and the fourth leading cause of cancer 
death in women worldwide (Bray et al., 2018).  Human papillomaviruses (HPV) are the 
main causes of CC in whichmore than 99% of CC tissues were infectedwith the DNA of 
the HPV virus(Monie, Hung, Roden, & Wu, 2008; Yuan et al., 2001). HPV also has a 
key role in other cancers such as vulva, anus, penis, vagina, mouth and throat 
cancer(Tommasino, 2014). HPV is a member of Papillomaviridea which infect squamous 
epithelium in different regions. The cellular structure of this virus consists of circular 
double-stranded DNA with approximately 8,000 bp that contains early regions that 
encodeearly viral proteins including (E6, E7, E8, E1, E2, E4, E5), late regions which 
encode capsid component proteins (L1 and L2), and anon coding region as long control 
region (LCR) which has a critical role in replication and transcription(Clifford, Smith, 
Plummer, Munoz, & Franceschi, 2003).L1 is the major protein in the capsid structure of 
HPV which weighs 55 kilo Dalton. Morphologically it is similar to virions and is made 
up of 72 pentamers called capsomers. This protein has a spontaneously self-assembling 
ability as virus like particles (VLPs). Assembled VLPs are considered to be strong 
immunogens that may be rapidly identified by B cells (Buck, Day, & Trus, 2013; Chen, 
Garcea, Goldberg, Casini, & Harrison, 2000; Kirnbauer, Booy, Cheng, Lowy, & Schiller, 
1992). It has been shown that injection of HPV16 L1-VLPs without adjuvant generates 
high levels of anti-HPV antibody responses (Harro et al., 2001; Tumban, Peabody, 
Peabody, & Chackerian, 2013). After the virus particles bind to the basal membrane, 
mature virus binds to the outer surface of the host cells using L1 protein. Then L1 
becomes pliable resulting in releasing the virus genome in the host cell and its 
replication(Buck et al., 2013).HPVs are classified into both mucosal and cutaneous 











(HR-HPV), depending on the lesion's power in developing progressive malignancy. Low-
risk mucosal HPVs produce genital warts; while high-risk HPVs produce squamous 
epithelial lesions and can cause invasive squamous carcinoma, such as CC(Clifford, 
Smith, Aguado, & Franceschi, 2003; Clifford, Smith, Plummer, et al., 2003; Kurman, 
Henson, Herbst, Noller, & Schiffman, 1994; Yuan et al., 2001; Zur Hausen, 1994). 
Studies have demonstrated that HPV16 and HPV18contribute toabout 70% of CC cases 
in which HPV16 and HPV18 are responsible for 51% and 16% of CC cases, 
respectively(Burd, 2003; Fernández‐San Millán et al., 2008; Muñoz et al., 2003; Tumban 
et al., 2013; Yuan et al., 2001). However, epidemiological and experimental studies have 
shown that other members of the α-paplumaviridea family also play a role in 
carcinogenesis(Fakhraei et al., 2016; Haghshenas et al., 2013). For instance, according to 
the international agency for research in cancer in 2012, 12 types of HPV including 
HPV16, HPV 18, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV56, 
HPV58 and HPV59 are responsible for CC and typesHPV26, HPV53, HPV66, HPV67, 
HPV68, HPV70 and HPV73, in rare cases, cause CC(Arbyn, Tommasino, Depuydt, & 
Dillner, 2014). Epidemiological studies suggest that CC could be prevented following the 
immunization against HPV infection through vaccination and that it could potentially 
decline CCfrequency(Roden & Wu, 2006). However, more knowledge about properties 
of this virus is needed for production and development of an effective vaccine(Monie et 
al., 2008). On other hand, production of an effective HPV vaccine can improve the 
prevention of cervix obstruction progress and reduce the treatment costs(Schiller & 
Lowy, 2012). Three VLP-based vaccines, Cervarix® bivalent vaccine (GlaxoSmithKline) 
and Gardasil® 4-valent and 9-valent vaccine have been introduced based on L1 antigen 










vaccines and native virions that lead to increase in antibody secretion, T cell cytotoxic 
activity and subsequently prevention of HPV infection. It is well-known that Cervarix® 
has a preventive maintenance against of HPV types 16 and 18. Also, it has been 
documented that Gardasil® 4-valent vaccine is remarked as a key protective against 
HPV16, HPV 18, HPV-6 and HPV-11. Gardasil® 9-valent causes protection againsta 
numbers of HPV types including31, 33, 45, 52, 16, 18, 6, 11, and 58(Negahdaripour et 
al., 2017; Panatto et al., 2015; Schiller & Lowy, 2014). But such vaccines should be 
purified from eukaryotic cells and they need more restricted cold chain for storage than 
those produce in prokaryotic system (Negahdaripour et al., 2017; Pouyanfard & Müller, 
2017; Zhai & Tumban, 2016).These facilities are not well-available in alldeveloping 
countries where 80% ofCC occurs(Ferlay et al., 2015). Therefore, manufacturing a safer 
and easier vaccine for wider use in the world is one of the most important health 
priorities.A HPV 16/18 bivalent vaccine, ceolin, has been well-characterized that it is 
produced in E.coli{Gu, 2017 #95} and entered phase III clinical trial{Hu, 2014 #96}{Wu, 
2015 #97}. Production of peptide vaccines is considered to be new targeted method that 
eliminates problems associated to current vaccines. Peptide vaccines are more commonly 
used than VLP-based vaccines. They are expressed in E.coli and are able to trigger high 
amount of humoral and cellular responses with high stability in room temperature(Naz & 
Dabir, 2007; Patronov & Doytchinova, 2013). Successfully, Immunoinformatics fields 
allow scientists to study epitopes, which in addition to reducing the numbers and 
facilitating experiments, which systematically leads to probable candidate epitopes 
identification besides facilitating experiments. As a result of new epitopes identification, 
the use of inactivated viral proteins could be eliminated(Naz & Dabir, 2007; 











vaccine based on L1 antigen of HPV type 16. This novel vaccine has two HPV epitopes 
that are able to stimulate the immune responses of CD4+ T, CD8+ T cells, humoral 
immunity, and interferon-γ (IFN-γ) production with higher antigenicity and no allergenic 
ability. In recent years, Toll-like receptor (TLR)-agonists were utilized as adjuvants. 
TLRs are a group of  Pattern Recognition Receptors (PRRs) that can activate the innate 
immune system through Pathogen Associated Molecular Patterns (PAMPs) and enhance 
presenting of antigens though antigen presenting cells (APC)(Jiménez-Dalmaroni, 
Gerswhin, & Adamopoulos, 2016; Reed, Hsu, Carter, & Orr, 2016). Given that TLR-4 
plays a natural role in controlling plenty of infectious diseases, a large number of 
adjuvants have been developed for TLR-4, some of them are available in commercial 
vaccines against HPV, such as Cervarix.  
These adjuvants by optimal activation of APCs increase the responsiveness of the vaccine 
(Fox, Friede, Reed, & Ireton, 2010; Giannini et al., 2006; Johnson, 2013). Flagellin, a 
TLR-5 agonist, causes activation of both innate and adaptive immune system(Fox et al., 
2010; Giannini et al., 2006; Johnson, 2013; Moyle, 2017; Moyle & Toth, 2013)and has 
been used as a vaccine adjuvant in several studies(Braga et al., 2010; Mori et al., 2012; 
Negahdaripour et al., 2017; Tarahomjoo, 2014). Therefore, in recent work, we focused 
on these two TLR-agonists as a potent adjuvant to enhance immunization in vaccine 
structure. Therefore, we evaluated structural stability, structural conformation, and its 
interaction with TLR-5 as well as solubility and successful expression of this structure in 
E.coli. Finally, in order to apply this vaccine to other HPVs, we used alignment of the 













2.  Materials and Methods 
2.1 Sequence retrieval 
The amino acid sequence of HPV16 L1 was retrieved from the NCBI 
(https://www.ncbi.nlm.nih.gov/) database with accession number of AAD33259.1 and 
saved in FASTA format for subsequent analysis. 
 
2.2 Epitope prediction 
2.2.1 Major histocompatibility complex class I (MHC-I) binding epitope prediction was 
performed by IEDB (www.iedb.org) database and Net-MHC 4.0 online server 
(http://www.cbs.dtu.dk/services/NetMHC/) and MHC-I humans allele with 9 mer length 
was selected. IEDB (Instructor/Evaluator Database)  as resource database includes a list 
of B and T cell epitopes and information about MHC, binding MHC ligand of human and 
animal species established by the National Institute of Allergy and Infectious Diseases. It 
uses artificial neural network (ANN), stabilized matrix method (SMM), Combinatorial 
Peptide Libraries (CombLib), and NetMHCpan, based on availability of predictors and 
previously observed predictive performances. These methods predict peptides binding to 
MHC class I molecules (Kim et al., 2012). NetMHC 4.0 software is one of the tools that 
quantitatively predict the interaction between MHC-I and peptides, because of owning 
artificial neural networks which allows insertions and deletions in the alignment does has 
a better performance than prediction methods based on peptides of single lengths 
(Andreatta & Nielsen, 2015). In the software, the thresholds for strong and weak binders 











2.2.2 CTL epitopes were determined using Combined Approach prediction in CTL 
Pread online server (http://crdd.osdd.net/raghava/ctlpred/index.html). CTL 
epitopes are the useful candidate for vaccine design which directly predicts 
CTL epitopes based on quantitative matrix (QM) and machine learning 
techniques such as Support Vector Machine (SVM), Artificial Neural 
Network (ANN) and facilitates MHC restriction in Tcell epitopes(Bhasin & 
Raghava, 2004).  
2.2.3 Prediction of MHC-ІІ binding epitopes was done by RANKPEP online server 
(http://imed.med.ucm.es/Tools/rankpep.html) that predicts MHC-II binding 
epitope using position specific scoring matrices (PSSMs)(Wang et al., 2008).  
2.2.4 Prediction of Linear B Cell epitopes was performed using LBtope 
(http://crdd.osdd.net/raghava/lbtope) and BepiPred2.0 
(http://www.cbs.dtu.dk/services/BepiPred). LBtope software is a method for 
prediction of B cell epitopes through SVM using dipeptide composition 
generated from the query amino acid sequence with an overall accuracy 
around 80%(Singh, Ansari, & Raghava, 2013). Then setting function was run 
onLBtope_Variable_non_redundant. 
BepiPred software 2.0 combines hidden Markov model and a propensity scale 
method and predicts the location of linear Bcell epitopes. When working with 
the BepiPred software on the results page of this software, the Epitope 
Threshold can be changed from zero to one, which indicates specificity and 
sensitivity of the interaction with the epitope(Larsen, Lund, & Nielsen, 2006).  
2.2.5 Selection of appropriate epitope: The results of all the above predictions were 











2.3 Evaluation of the selected epitopes; Based on IFN-γ inducing epitopes, 
antigenicity and allergenicity epitopes prediction 
2.3.1 Selected epitopes were assessed using IFNepitope server 
(http://crdd.osdd.net/raghava/ifnepitope) to determine the ability of epitopes to 
induce IFN-γ production. This web server classifies MHC binder epitopes into 
IFN-γ inducing (positive numbers) and non-inducing IFN-γ (negative numbers). 
Several methods apply in this software including; machine learning technique, 
motifs-based search, and hybrid approach were used for classification. Best 
prediction based on hybrid approach has 82.10% accuracy whereas the hybrid 
approach has maximum accuracy of 81.39% (Dhanda, Vir, & Raghava, 2013). To 
evaluateepitope prediction in this software, FASTA format of sequence will enter 
in respective box and in setting was evaluated Motif and SVM hybrid and IFN-γ 
versus Non IFN-γ. 
2.3.2 Antigencity of epitopes was assessed via ANTIGENpro server 
(http://scratch.proteomics.ics.uci.edu/) and VaxiJen v2.0 (http://www.ddg-
pharmfac.net/vaxijen/VaxiJen/VaxiJen.html).Web server of ANTIGENpro is the 
first server for predicting antigenicity based on protein sequence, which is often 
done by protein microarray data analysis (Magnan et al., 2010). To predict 
antigenic epitopes, the sequence of selected epitopes was entered into the 
corresponding box and then run the ANTIGENpro method.VaxiJen is the first 
server for prediction of antigens, which is available free online. Prediction bases 
of this server is based on physicochemical properties protein amino acid 
sequences instead of a sequence alignment approach(Doytchinova & Flower, 











FASTA sequence of the protein was given to the software and virus word was 
selected in the box of the target and set the threshold on 0.4, and then submission 
was performed . 
2.3.3 Allergenicity of selected epitopes was assessed using AllergenFP v.1.0 
(http://ddg-pharmfac.net/AllergenFP/). This server identifies allergens based on 
their physicochemical properties. Accuracy of this server is about 88% (Dimitrov, 
Naneva, Doytchinova, & Bangov, 2013). After mentioned Steps, appropriate 
epitopes were chosen based on above stages. 
 
2.4 Alignment of selected epitopes in family members of α-papillomaviridea 
To understand that selected epitopes are conserved in family members of α-
papillomaviridea, we aligned the selected epitopes in HPV16 and other α-
papillomaviridea family members. First, the amino acid sequence of L1 of α-
papillomaviridea family members was retrieved from the NCBI 
(https://www.ncbi.nlm.nih.gov/) database then blast of epitopes was done using 
CLC sequence viewer 8.0. CLC sequence viewer is one of the software for 
viewing and analyzing alignment of  the protein, RNA and DNA(Sarwar, 
Rehman, & Ferzund, 2016).  
2.5 Vaccine engineering, evaluation of construct physicochemical properties, 
antigenicity and allergenicity 
The epitopes were selected based on the results of the previous sections, and the 
whole construction was designed by joining these epitopes to two TLR agonist 











of Salmonella enterica subsp. as TLR-5). After designing the vaccine, the 
physicochemical properties of the vaccine structure including the number of 
amino acids, molecular weight, number and composition of atoms, molecular 
formula, number of positive and negative amino acid compounds, total number of 
positive and negative residues, isoelectric point (pI), instability index, aliphatic 
index and grand average hydropath city (GRAVY) were evaluated by 
Expasy’sProtParam online server (http://web.expasy.org/protparam/)(Gasteiger 
et al., 2005) and the solubility of vaccine protein in E. coli was evaluated by two 
severs: ccSOL  omics server 
(http://service.tartaglialab.com/grant_submission/ccsol_omics) and Solpro 
(http://scratch.proteomics.ics.uci.edu). ccSOL omics is a web server that predicts 
solubility of proteins in E. coli based on  coil/disorder, hydrophobicity Β-sheet 
and α-helix properties. Accuracy of this server is 74% (Agostini, Cirillo, Livi, 
Delli Ponti, & Tartaglia, 2014). Solpro is another web server that predicts 
solubility of proteins upon overexpression in E. coli. This server has an accuracy 
of higher than 74% using multiple runs of 10-fold cross validation (Magnan, 
Randall, & Baldi, 2009). Allergenicity of vaccine was assessed using AllergenFP 
v.1.0 (http://ddg-pharmfac.net/AllergenFP/) and its antigenicity was assessed by 
ANTIGENpro server (http://scratch.proteomics.ics.uci.edu) and VaxiJen 2.0 
(http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html) at a threshold 
value 0.4. 
 











The prediction of Tertiary structure (3D) model was determined using I-TASSER 
online server (https://zhanglab.ccmb.med.umich.edu/I-TASSER/). I-TASSER 
server is a modeling server of protein tertiary structure based on secondary-
structure enhanced Profile-Profile threading Alignment (PPA) and iterative 
implementation of the Threading Assembly Refinement (TASSER) program. In 
this server unlike many MQAP programs that evaluate models solely based on the 
structure of the final models, the performance scoring includes simulation 
information and modeling parameters. This software is free for university users 
and allows them to automatically design high-quality models of 3-D protein 
structure based on their amino acid sequences(Yang & Zhang, 2015). This server 
presents five models as a result of the prediction. Therefore, the model with 
highest confidence score (c-score) was accepted and observed with Pymol 
software v2.1.1. Pymol is one of the most software tools to visualize  molecular 
structure(Shin, Lee, Heo, Lee, & Seok, 2014). After that, Galaxy Refine was used 
to determine the refinement of3D model. Galaxy Refine is an open source online 
software in which was successfully tested in CASP10 (Critical assessment of 
techniques for protein structure prediction) as a refinement method. This method 
first rebuilt the side chains of protein using molecular dynamic simulationside-
chain repacking and also overall structure relaxation. According to the assessment 
report of CASP10, this method indicates the best performance in quality 
improvement in local structure, as well as it can improve quality of global and 
local structure, also it can improve quality of both global and local structure(Shin 











Finally, to validate the refined 3D structures and compare the models, The 
RAMPAGE (Ramachandran Plot Assessment) 
(http://mordred.bioc.cam.ac.uk/~rapper/rampage.php), and ERRAT 
(http://services.mbi.ucla.edu/ERRAT/) servers were used. Rampage analysis 
backbone conformation through calculation of phi-psi torsion angles for amino 
acids in the structure. Then classified the amino acids in 3 region of favored, 
allowed and outlier(Lovell et al., 2003). ERRAT is a web server that evaluates the 
validation of protein structure based on characteristic atomic interaction. This 
server compares the statistics of non-bonded atom–atom interactions in the query 
sequence with a database of 96 reliable high-resolution crystallography structures. 
This server is sensitive to errors in position of backbone atoms on the order of 1.5 
Aº and method used for atomic refinement so that unrefined structures generally 
do not score well(Colovos & Yeates, 1993). Discontinuous Bcell epitopes were 
predicted from the 3D structure of the vaccine by Disco Tope 2.0 server 
(http://www.cbs.dtu.dk/services/DiscoTope/). This server calculates the final 
scores by two approaches: contact numbers derived from surface accessibility and 
a novel epitope propensity amino acid score(Kringelum, Lundegaard, Lund, & 
Nielsen, 2012). The default threshold value was set on-3.7 in which the sensitivity 
and specificity are 0.47 and 0.75, respectively. 
2.7 Exploration of interaction between vaccine and human Toll like receptor 5 
First, the three-dimensional structure of the TLR-5 was obtained from PDB data 
base (www.rcsb.org) with code of 3J0A. Then protein-protein docking of vaccine 











(cluspro.bu.edu/login.php). CLUSPRO 2.0 is a web server for protein-protein 
docking that assays direct docking of two interacting proteins in 3 stages: 
1. Running of PIPER (a rigid body docking program based on the Fast 
Fourier Transform (FFT) correlation approach). 
2. RMSD which based on clustering of the structures generated was done to 
find the largest clusters that will represent the most likely models of the 
complex. 
3. Analyzing stability of the clusters and refinement of structure were carried 
out by short Monte Carlo simulations and the medium‐range optimization 
method SDU, respectively (Kozakov et al., 2013; Kozakov et al., 2010). 
To do molecular docking study by this software, the candidate vaccine was 
considered as a ligand and TLR-5 considered as a receptor. 
2.8 Codon optimization and in silico cloning 
In order to prepare a suitable vaccine sequence to be clone and express in an appropriate 
expression vector, the reverse translation and codon optimization of the designed vaccine 
sequencewas performed by the Codon Usage Wrangler server (https://www.mrc-
lmb.cam.ac.uk/ms/methods/codon.html). Properties of the optimized DNA sequence 
such as Codon Adaptation Index (CAI), GC content, Codon Frequency and Distribution 
(CFD) have a key role in achieving a high-level of protein expression in the host. 
Therefore, the mentioned properties were assessed by GenScript online server 
(https://www.genscript.com/tools/rare-codon-analysis)(Negahdaripour et al., 2017)and  
finally, the restriction sites of ECORI and BamHIwere added to the N- and C-terminals 











3.1 Primary structure 
The protein sequence of HPV16 L1 with accession number of AAD33259.1 was driven 
in NCBI . 
3.2 Epitope prediction 
3.2.1 MHC-I binding epitope prediction 
MHC-I binding epitope with a length of 9-mer was predicted by database of IEDB 
and NetMHC 4.0. MHC-I binding epitopes that have an overlap in IEDB and 
NetMHC 4.0 were selectedfor future studies. 
3.2.2 Prediction of CTL epitopes 
Prediction of CTL epitopes was done by free online server CTL Pred. The prediction 
result of this server is given in several formats, including overlap display, color display, 
and a tabular display. In the color display format, predicted epitopes of CTL are indicated 
by staining. The beginning amino acid of each epitope is indicated by a red color and 
other amino acids are blue. The results are displayed in 100 amino acid columns per line. 
This format is very useful in detecting accumulation regions of CTL epitopes in a 
sequence. In overlap display, all CTL epitopes are displayed in separate lines. This 
display is presented on a scale that indicates the position of the epitope in the antigenic 
sequence and epitopes are displayed by staining of amino acids and final output format is 
tabular that is the most commonly displayed format. This format is widely used by most 
predictive methods. In this format, peptides are displayed in a table according to low 
scoring. Sequences that overlap in the results of all three formats are selected for 
subsequent studies. 











MHC-II binding epitope of L1 was done using RANKPEP. 
3.2.4 Linear B cell epitope prediction 
This prediction was done by two servers separately and their results were compared. 
1) LBtope: On the result page of this software, a colorful block is shown for each 
sequence. The color of each residue displays the percentage of the probability 
that the amino acid is in the middle of the motif. So the possibility of 
immunodominantepitpe arranged based on colors in which red for 81-100%, 
green for 61-80%, blue for 41-60%, yellow for 21-40%, and black for 0-20%. 
Albeit there was no yellow and block colors in our sequence. Motifs that have 
a possibility above 80% were considered as epitopes. 
2) BepiPred: The prediction results are shown with several bars. The first bar 
contains the amino acid sequence of the protein in which characterized by 
orange color and more colorful bar has higher percentage of residue in epitope. 
Amino acids that have a threshold 0.5 or higher were indicated with the 
symbol E above the amino acids. Second bars indicate the protein structure. 
In this bar, pink, blue, and orange colors to indicate helix, sheet and coil, 
respectively. Exposed epitopes are indicated with a capital letter E and buried 
epitopes are indicated with a capital letter B. Overlapping epitopes were 
selected in two servers for future studies. 
3.3 Selection of appropriate epitopes 
The obtained results from all above predictions were compared to each other in order to 











3.4 Evaluation of the predicted-epitopes based on IFN-γ inducing, 
Allergenicity and Antigenicity 
Table 1 shows the results of prediction of allergenicity and antigenicity in selected 
epitpes. The selected epitopes were evaluated by IFNepitope server software to determine 
which of them had a better ability to induce IFN-γ. Antigenic capacity of selected epitopes 
were assessed by ANTIGENpro and vaccijen2.0 servers. In addition, allergenicity 
properties were also predicted by AllergenFP v.1.0. 
3.5 Confirmation of conservativity of selected epitopes in all members of the α-
papilloma viridea family  
Conservation of selected epitopes in members of the α-papillomaviridea family (Types 
HPV 26, 51, 69, 82, 30, 53, 56, 66, 18, 39, 45, 59, 68, 70, 85, 97, 16, 31, 33, 35, 52, 58, 
67, 34and 73) were assessed by retrieve L1 sequence in members of the α-
papillomaviridea family in NCBI. Alignment was carried out in CLC Sequence viewer 
8.0.  As it has shown in Fig 1, alignment of L1 sequences indicated that screening 
peptides, especially in anchoring amino acids 2, 8 and 9, are found to share high sequence 
similarity among all members of α-papillomaviridea family.  
 
3.6 Vaccine engineering and evaluation of physicochemical properties of the 
candidate vaccine structure, antigenicity and allergencity 
Peptide sequences of YGDSLFFYLRREQMFVRH and YVARTNIYYHAGTSRLLAV 
GHPYFPIK were selected as immunodominant epitopes in the vaccine structure.  These 
epitopes are joined to two TLR agonist adjuvants: RS09 that is a short peptide TLR-4 











agonist of TLR-5. A short linker sequence of GGS was used to link peptide sequences to 
each other and with two TLR agonist adjuvants. Finally, the vaccine structure that is a 
peptide with 278 amino acids was designed by linking the sequences. Fig. 2 shows the 
schematic diagram of the vaccine was designed by Illustrator for Biological Sequences 
(IBS)Ver 1.0 server (61). 
Physicochemical properties and molecular structure of the designed vaccine were 
analyzed by ProtParam server (Table 2). The results showed that the vaccine is stable 
(instability index: 39.94) with a molecular weight (29.96 KDa) and isoelectric point (pI: 
7.97). Since protein insolubility is a major problem for many experimental studies, 
therefore, we should examine the status of protein solubility upon overexpression.   
ccSOL omics  and Solpro servers predicted the probability of the vaccine solubility upon 
expression in E. coli host is 25% and 0.544158, respectively. These findings emphasize 
that our designed peptide vaccine is soluble (Table 2). In addition, prediction of consensus 
antigenicity of candidate vaccine using predictions using ANTIGENpro and vaccijen 2.0 
tools revealed that the final whole protein construct is as an antigen. Meanwhile, the result 
of AllergenFP tool showed that our construct has no allergenic properties.   
3.7 Tertiary structure analysis and prediction of discontinuous B-cell epitopes 
Tertiary structure analysis was examined using I-TASSER, Pymol, Galexi Refine, 
ERRAT and RAMPAGE (Fig. 3 and Fig. 4 and Table 3). Discontinuous B-cell epitopes 










3.8 Molecular docking of the vaccine with TLR-5 
To evaluate the interaction of TLR-5 with the candidate vaccine structure, protein-protein 
docking of 3D models was performed using the Cluspro 2.0 online software (Fig.5). The 
lower Gibs free energy for an interaction of TLR5-vaccine model was -1274.6J. 
3.9 Codon optimization and in silico cloning 
CFD means rare codons that decrease efficiency of translation and even hind the 
translational machinery. These results indicate that the optimized DNA sequence of the 
vaccine construction is suitable for cloning and expression in E.coli (Fig.6). 
Finally, restriction sites of EcoRІ and BamHІ were inserted at the start and end of the 
DNA sequence, respectively. Finally, the genetic vaccine was prepared for cloning and 
expression in E. coli. 
4. Discussion 
Oncogenic human papillomaviruses are the main causes of CC (Monie et al., 2008; Yuan 
et al., 2001). These viruses are also involved in the initiation and development of other 
cancers, such as Vulva, Anus, Penis, Vagina, Mouth, Throat and gastric cancer (Fakhraei 
et al., 2016; Tarahomjoo, 2014). L1 is the main protein in the capsid structure of these 
viruses that has a role key in infection (Buck et al., 2013; Chen et al., 2000; Kirnbauer et 
al., 1992). Producing of a vaccine on L1 protein can lead to immunization against HPV 
infection to potentially and prevent related cancers (Roden& Wu, 2006). Available HPV 
vaccines have not protective coverage against all of HPV types (Arbyn et al., 2014), also 
these vaccines should be purified in eukaryotic cells in which meet some obstacles in 











highly increase cost of vaccination program in middle and low income developing 
countries, where about 80% of CC exist (Ferlay et al., 2015; Pouyanfard & Müller, 2017; 
Zhai &Tumban, 2016). Therefore, thorough efforts should be made to replace existing 
vaccines with cheaper vaccines and more stable at room temperature. Moreover, the 
efficacy of candidate vaccine should be large enough to produce strong humoral and 
cellular immune responses against the most important HPV types that are known to cause 
CC and other HPV associated cancers. In order to develop a vaccine using bioinformatics, 
two sequences were identified as a capable epitopes, which activates humoral response, 
Th1 and CTL cells. Unlike having high antigenicity, the vaccine should not be allergic. 
The sequence of the immunodominant epitopes must be selected in such a way as to 
maximize structural similarity among the members of α-papillomaviridea family.  
Using an appropriate adjuvant for vaccine production may enhance the efficacy of target 
antigens, potency and stability of vaccine in individuals who do not respond well to the 
vaccine. Using the adjuvants in the vaccine structure produces stronger and longer 
immune responses. In recent years, TLR agonists have been used as adjuvants in the 
vaccine structure and their use has been increasingly developed (Jiménez-Dalmaroni et 
al., 2016). TLR-4 has been reported to express in various regions of the cervix. On the 
other hand, Giannini et al revealed that the use of monophosphoryl lipid A (MPL) and 
aluminum salt as TLR-4 agonist in Cervarix vaccine this drug as a saline agonist in 
comparison to aluminum salt alone has a greater effect on the induction and elongation 
of immune response (Giannini et al., 2006). We used RS09 as a successful synthetic TLR-
4 agonist peptide that resembles LPS by interacting with TLR-4 (Shanmugam et al., 











significantly increase cellular and humoral immune responses and so that it is more 
beneficial (Kasturi et al., 2011; Orr et al., 2014; Zhu et al., 2010).  
Flagellin improves innate and acquired immunity by increasing cytokine production using 
a variety of innate cell types, attracting T and B cells into the secondary lymphoid sites, 
and activating TLR5 , CD11c+ , and T lymphocyte cells in a separate method of cognate-
Ag recognition, Therefore it has been used in vaccine structure as an adjuvant. 
Furthermore, it has also been shown that TLR5 is present in the cervix (Fazeli, Bruce, 
&Anumba, 2005; Hayashi et al., 2001; Lu & Sun, 2012; Nguyen et al., 2013; Tarahomjoo, 
2014; Yoon et al., 2012).That’s why we used the flagellin of Salmonella enterica subsp. 
enterica serovar Dublin (TLR5 agonist) as the second adjuvant in vaccine structure. It has 
been demonstrated that flagellin has 4 domains including D0, D1, D2, and D3.  Only the 
D0 and D1 domains have N- termini and C-termini of the molecule interact with the TLR5 
and its D2 and D3 domains are responsible for antigenicity (Lu & Sun, 2012; Song, Jeon, 
Namgung, Hong, & Yoon, 2017; Yonekura, Maki-Yonekura, &Namba, 2003; Yoon et 
al., 2012). In line to other studies, D2 and D3 domains of flagellin were deleted and only 
the N- and C- termini of the flagellin were used in head and tail sections of the vaccine 
structure (Hajighahramani et al., 2017). Studies have proven that the use of linkers in 
multi-epitope vaccines would be useful for facilitating antigen processing and avoiding 
the formation of junctional epitopes (Livingston et al., 2002; Nezafat et al., 2016). 
Therefore, GGS linkers were used to join different vaccine sections (Negahdaripour et 
al., 2017). The small, non-polar glycine and polar serine amino acids cause flexibility and 
solubility of the vaccine structure (Argos, 1990; Bhattacharya, Nowotny, Cao, & Cheng, 
2016). Since N- and C- termini of flagellin can interact freely with TLR5, no linker was 











designed with 278 amino acids. In addition to activating effective immune responses, an 
efficient vaccine must have good physicochemical properties during production, 
formulation, storage and administration. Based on the results of bioinformatics 
predictions, our designed vaccine was soluble, stable, non-allergen, immunogen with pI 
7.97. Furthermore, according to the results of Ramachandran plot and ERRAT 
evaluations the vaccine structure was refined, which led to a higher quality. The capacity 
of the final structure of candidate vaccine in inducing humoral response was assessed in 
Discotope 2.0 which predicts conformational B cell epitope, and their results reveal the 
vaccine is a strong immunogenic peptide. After the design of a high-quality vaccine, its 
interaction with TLR5 was evaluated by CLUSPRO2.0 docking online software. It found 
that our construct interacted efficiently with TLR5 with a negative Gibs free energy.   
To have a high throughput recombinant protein expression in prokaryotic system, 
GenScript tool was shown higher expression efficacy of the full length peptide vaccine 
in E. coli host.  Also the high solubility protein which was predicted by the Solpro and 
ccsolomics software is another positive feature of the vaccine that prevents the 
accumulation of protein in the inclusion bodies. The results showed our designed vaccine 
is suitable to be used against cervical cancer. We added appropriate sequence of 
restriction enzymes to two N- and C-terminus of the DNA vaccine construct. The final 
vaccine construct might be expressed in E. coli and used to prevent the HPV virus 
infections to reduce the burden of cervical cancer and other HPV related cancers. 
Although the outputs of bioinformatics softwares confirm high immunogenicity of the 
modeled multiepitopes HPV vaccine, the presence of low accessibility B cell linear 
epitope might be a limitation in our study. 











In this study, using several available bioinformatics tools, we tried to design an efficient 
HPV peptide vaccine by using two specific immunodominant epitopes. The vaccine is 
able to induce humoral and cell-mediated immunities, which are required for protection 
against all types of HPV viruses. It is comprise of several adjuvants to increase immunity. 
The physicochemical properties of the structure were shown to be appropriate by using 
computational tools. Thus, this vaccine might be expected to prevent the HPV infections 
and other HPV-related cancers. 
6. List of abbreviations 
abbreviation Full name 
Ag  Antigen        
Aº Angstrom 
bp base pair        
CD Cluster of Differentiation 
CTL Cytotoxic T-Lymphocyte 
D Domain 
HPV human papilloma viruses     
hTLR-5 Human toll like receptor 5 
IFN-γ Interferon gamma 
J Joule 
LPS lipopolysaccharide 
MHC-I Major histocompatibility complex class I 
MHC-ІІ Major histocompatibility complex class ІІ 
PI Isoelectric point 














Zahra Yazdani collecting and interpretation of data, performing the analysis and writing the 
draft. 
Alireza Rafiei supervision the project, analyzing and interpreting the results and editing of 
manuscript. 
Reza Valadan having technical help revised the manuscript critically. 
Hossein Ashrafi having technical help revised the manuscript critically. 
MarziehSharifi Pasandi screeching and editing of manuscript.  
Mostafa Kardan screeching and editing of manuscript 
All authors read and approved the final manuscript. 
Funding 
This study received a small grant (Grant no: 5269) from Research and Technology 
deputy of Mazandaran University of Medical Sciences. 
Availability of data and materials 
In this study, protein sequence of HPV16 L1 was obtained from NCBI 
(https://www.ncbi.nlm.nih.gov/) and analyzed by different software. 
Authors’ contributions 
Z.Y contributed to collecting and interpretation of data, performing the analysis and 
writing the draft. A.R supervised the project and analyzed and interpreted the results 











critically. M.S and M.K contributed in screeching and editing of manuscript. All authors 
read and approved the final manuscript. 
Ethics approval and consent to participate 
The protocol of this study approved by Research Ethics committee of Mazandaran 
University of Medical Sciences 
Consent for publication 
Not applicable. 
Declarations of interest 
The authors declared no conflict of interest. 
Acknowledgements 
The authors would like to cordially thank Seyed Ahmad Mohammadi for his helpful 
advices. 
References 
Agostini, F., Cirillo, D., Livi, C. M., Delli Ponti, R., & Tartaglia, G. G. (2014). cc SOL omics: A 
webserver for solubility prediction of endogenous and heterologous expression in 
Escherichia coli. Bioinformatics, 30(20), 2975-2977.  
Andreatta, M., & Nielsen, M. (2015). Gapped sequence alignment using artificial neural 
networks: application to the MHC class I system. Bioinformatics, 32(4), 511-517.  
Arbyn, M., Tommasino, M., Depuydt, C., & Dillner, J. (2014). Are 20 human papillomavirus 
types causing cervical cancer? The Journal of pathology, 234(4), 431-435.  
Bhasin, M., & Raghava, G. (2004). Prediction of CTL epitopes using QM, SVM and ANN 
techniques. Vaccine, 22(23-24), 3195-3204.  
Braga, C. J., Massis, L. M., Sbrogio-Almeida, M. E., Alencar, B. C., Bargieri, D. Y., Boscardin, S. B., 
. . . Ferreira, L. C. (2010). CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live 
vaccine vectors or as purified protein. Vaccine, 28(5), 1373-1382.  
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer 
statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 











Buck, C. B., Day, P. M., & Trus, B. L. (2013). The papillomavirus major capsid protein L1. 
Virology, 445(1-2), 169-174.  
Burd, E. M. (2003). Human papillomavirus and cervical cancer. Clinical microbiology reviews, 
16(1), 1-17.  
Chen, X. S., Garcea, R. L., Goldberg, I., Casini, G., & Harrison, S. C. (2000). Structure of small 
virus-like particles assembled from the L1 protein of human papillomavirus 16. 
Molecular cell, 5(3), 557-567.  
Clifford, G., Smith, J., Aguado, T., & Franceschi, S. (2003). Comparison of HPV type distribution 
in high-grade cervical lesions and cervical cancer: a meta-analysis. British journal of 
cancer, 89(1), 101.  
Clifford, G., Smith, J., Plummer, M., Munoz, N., & Franceschi, S. (2003). Human papillomavirus 
types in invasive cervical cancer worldwide: a meta-analysis. British journal of cancer, 
88(1), 63.  
Colovos, C., & Yeates, T. O. (1993). Verification of protein structures: patterns of nonbonded 
atomic interactions. Protein science, 2(9), 1511-1519.  
Dhanda, S. K., Vir, P., & Raghava, G. P. (2013). Designing of interferon-gamma inducing MHC 
class-II binders. Biology direct, 8(1), 30.  
Dimitrov, I., Naneva, L., Doytchinova, I., & Bangov, I. (2013). AllergenFP: allergenicity prediction 
by descriptor fingerprints. Bioinformatics, 30(6), 846-851.  
Doytchinova, I. A., & Flower, D. R. (2007). Identifying candidate subunit vaccines using an 
alignment-independent method based on principal amino acid properties. Vaccine, 
25(5), 856-866.  
Fakhraei, F., Haghshenas, M. R., Hosseini, V., Rafiei, A., Naghshvar, F., & Alizadeh‑Navaei, R. 
(2016). Detection of human papillomavirus DNA in gastric carcinoma specimens in a 
high-risk region of Iran. Biomedical reports, 5(3), 371-375.  
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., . . . Bray, F. (2015). 
Cancer incidence and mortality worldwide: sources, methods and major patterns in 
GLOBOCAN 2012. International journal of cancer, 136(5), E359-E386.  
Fernández‐San Millán, A., Ortigosa, S. M., Hervás‐Stubbs, S., Corral‐Martínez, P., Seguí‐Simarro, 
J. M., Gaétan, J., . . . Veramendi, J. (2008). Human papillomavirus L1 protein expressed 
in tobacco chloroplasts self‐assembles into virus‐like particles that are highly 
immunogenic. Plant biotechnology journal, 6(5), 427-441.  
Fox, C. B., Friede, M., Reed, S. G., & Ireton, G. C. (2010). Synthetic and natural TLR4 agonists as 
safe and effective vaccine adjuvants. In Endotoxins: structure, function and recognition 
(pp. 303-321): Springer. 
Gasteiger, E., Hoogland, C., Gattiker, A., Wilkins, M. R., Appel, R. D., & Bairoch, A. (2005). 
Protein identification and analysis tools on the ExPASy server. In The proteomics 
protocols handbook (pp. 571-607): Springer. 
Giannini, S. L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., . . . Losonksy, G. 
(2006). Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP 
vaccine formulated with the MPL/aluminium salt combination (AS04) compared to 
aluminium salt only. Vaccine, 24(33-34), 5937-5949.  
Haghshenas, M., Golini-Moghaddam, T., Rafiei, A., Emadeian, O., Shykhpour, A., & Ashrafi, G. 
H. (2013). Prevalence and type distribution of high-risk human papillomavirus in 
patients with cervical cancer: a population-based study. Infectious agents and cancer, 
8(1), 20.  
Harro, C. D., Pang, Y.-Y. S., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., . . . Karron, R. 
A. (2001). Safety and immunogenicity trial in adult volunteers of a human 
papillomavirus 16 L1 virus-like particle vaccine. Journal of the National Cancer 










Jiménez-Dalmaroni, M. J., Gerswhin, M. E., & Adamopoulos, I. E. (2016). The critical role of toll-
like receptors—from microbial recognition to autoimmunity: a comprehensive review. 
Autoimmunity reviews, 15(1), 1-8.  
Johnson, D. A. (2013). TLR4 agonists as vaccine adjuvants: a chemist’s perspective. Expert 
review of vaccines, 12(7), 711-713.  
Kim, Y., Ponomarenko, J., Zhu, Z., Tamang, D., Wang, P., Greenbaum, J., . . . Bourne, P. E. 
(2012). Immune epitope database analysis resource. Nucleic acids research, 40(W1), 
W525-W530.  
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D., & Schiller, J. (1992). Papillomavirus L1 major capsid 
protein self-assembles into virus-like particles that are highly immunogenic. 
Proceedings of the National Academy of Sciences, 89(24), 12180-12184.  
Kozakov, D., Beglov, D., Bohnuud, T., Mottarella, S. E., Xia, B., Hall, D. R., & Vajda, S. (2013). 
How good is automated protein docking? Proteins: Structure, Function, and 
Bioinformatics, 81(12), 2159-2166.  
Kozakov, D., Hall, D. R., Beglov, D., Brenke, R., Comeau, S. R., Shen, Y., . . . Paschalidis, I. C. 
(2010). Achieving reliability and high accuracy in automated protein docking: ClusPro, 
PIPER, SDU, and stability analysis in CAPRI rounds 13–19. Proteins: Structure, Function, 
and Bioinformatics, 78(15), 3124-3130.  
Kringelum, J. V., Lundegaard, C., Lund, O., & Nielsen, M. (2012). Reliable B cell epitope 
predictions: impacts of method development and improved benchmarking. PLoS 
computational biology, 8(12), e1002829.  
Kurman, R. J., Henson, D. E., Herbst, A. L., Noller, K. L., & Schiffman, M. H. (1994). Interim 
guidelines for management of abnormal cervical cytology. JOURNAL-AMERICAN 
MEDICAL ASSOCIATION, 271, 1866-1866.  
Larsen, J. E. P., Lund, O., & Nielsen, M. (2006). Improved method for predicting linear B-cell 
epitopes. Immunome research, 2(1), 2.  
Lovell, S. C., Davis, I. W., Arendall III, W. B., De Bakker, P. I., Word, J. M., Prisant, M. G., . . . 
Richardson, D. C. (2003). Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. 
Proteins: Structure, Function, and Bioinformatics, 50(3), 437-450.  
Magnan, C. N., Randall, A., & Baldi, P. (2009). SOLpro: accurate sequence-based prediction of 
protein solubility. Bioinformatics, 25(17), 2200-2207.  
Magnan, C. N., Zeller, M., Kayala, M. A., Vigil, A., Randall, A., Felgner, P. L., & Baldi, P. (2010). 
High-throughput prediction of protein antigenicity using protein microarray data. 
Bioinformatics, 26(23), 2936-2943.  
Monie, A., Hung, C.-F., Roden, R., & Wu, T. C. (2008). Cervarix™: a vaccine for the prevention of 
HPV 16, 18-associated cervical cancer. Biologics: targets & therapy, 2(1), 107.  
Mori, J., Vranac, T., Smrekar, B., Černilec, M., Šerbec, V. Č., Horvat, S., . . . Jerala, R. (2012). 
Chimeric flagellin as the self-adjuvanting antigen for the activation of immune 
response against Helicobacter pylori. Vaccine, 30(40), 5856-5863.  
Moyle, P. M. (2017). Biotechnology approaches to produce potent, self-adjuvanting antigen-
adjuvant fusion protein subunit vaccines. Biotechnology advances, 35(3), 375-389.  
Moyle, P. M., & Toth, I. (2013). Modern subunit vaccines: development, components, and 
research opportunities. ChemMedChem, 8(3), 360-376.  
Muñoz, N., Bosch, F. X., De Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., . . . Meijer, C. J. 
(2003). Epidemiologic classification of human papillomavirus types associated with 
cervical cancer. New England Journal of Medicine, 348(6), 518-527.  
Naz, R. K., & Dabir, P. (2007). Peptide vaccines against cancer, infectious diseases, and 
conception. Frontiers in bioscience: a journal and virtual library, 12, 1833-1844.  
Negahdaripour, M., Eslami, M., Nezafat, N., Hajighahramani, N., Ghoshoon, M. B., Shoolian, E., 











immunoinformatics and structural vaccinology approaches. Infection, Genetics and 
Evolution, 54, 402-416.  
Panatto, D., Amicizia, D., Bragazzi, N. L., Rizzitelli, E., Tramalloni, D., Valle, I., & Gasparini, R. 
(2015). Human papillomavirus vaccine: State of the art and future perspectives. In 
Advances in protein chemistry and structural biology (Vol. 101, pp. 231-322): Elsevier. 
Patronov, A., & Doytchinova, I. (2013). T-cell epitope vaccine design by immunoinformatics. 
Open biology, 3(1), 120139.  
Pouyanfard, S., & Müller, M. (2017). Human papillomavirus first and second generation 
vaccines–current status and future directions. Biological chemistry, 398(8), 871-889.  
Reed, S. G., Hsu, F.-C., Carter, D., & Orr, M. T. (2016). The science of vaccine adjuvants: 
advances in TLR4 ligand adjuvants. Current opinion in immunology, 41, 85-90.  
Roden, R., & Wu, T.-C. (2006). How will HPV vaccines affect cervical cancer? Nature Reviews 
Cancer, 6(10), 753.  
Sarwar, M. A., Rehman, A., & Ferzund, J. (2016). Database Search, Alignment Viewer and 
Genomics Analysis Tools: Big Data for Bioinformatics. International Journal of 
Computer Science and Information Security, 14(12), 317.  
Schiller, J. T., & Lowy, D. R. (2012). Understanding and learning from the success of 
prophylactic human papillomavirus vaccines. Nature Reviews Microbiology, 10(10), 
681.  
Schiller, J. T., & Lowy, D. R. (2014). Raising expectations for subunit vaccine. The Journal of 
infectious diseases, 211(9), 1373-1375.  
Shin, W.-H., Lee, G. R., Heo, L., Lee, H., & Seok, C. (2014). Prediction of protein structure and 
interaction by GALAXY protein modeling programs. Bio Design, 2(1), 1-11.  
Singh, H., Ansari, H. R., & Raghava, G. P. (2013). Improved method for linear B-cell epitope 
prediction using antigen’s primary sequence. PloS one, 8(5), e62216.  
Tarahomjoo, S. (2014). Utilizing bacterial flagellins against infectious diseases and cancers. 
Antonie Van Leeuwenhoek, 105(2), 275-288.  
Tommasino, M. (2014). The human papillomavirus family and its role in carcinogenesis. Paper 
presented at the Seminars in cancer biology. 
Tumban, E., Peabody, J., Peabody, D. S., & Chackerian, B. (2013). A universal virus-like particle-
based vaccine for human papillomavirus: longevity of protection and role of 
endogenous and exogenous adjuvants. Vaccine, 31(41), 4647-4654.  
Wang, P., Sidney, J., Dow, C., Mothe, B., Sette, A., & Peters, B. (2008). A systematic assessment 
of MHC class II peptide binding predictions and evaluation of a consensus approach. 
PLoS computational biology, 4(4), e1000048.  
Yang, J., & Zhang, Y. (2015). I-TASSER server: new development for protein structure and 
function predictions. Nucleic acids research, 43(W1), W174-W181.  
Yuan, H., Estes, P. A., Chen, Y., Newsome, J., Olcese, V. A., Garcea, R. L., & Schlegel, R. (2001). 
Immunization with a pentameric L1 fusion protein protects against papillomavirus 
infection. Journal of virology, 75(17), 7848-7853.  
Zhai, L., & Tumban, E. (2016). Gardasil-9: A global survey of projected efficacy. Antiviral 
research, 130, 101-109.  
Zur Hausen, H. (1994). Molecular pathogenesis of cancer of the cervix and its causation by 














Fig. 1 Alignment of selected epitopes in α-papillomaviridea:  (a) Alignment of selected 
epitopes in HPV-16 and α-5 species, b)  Alignment of selected epitopes in HPV-16 and 
α-6 species, c) Alignment of selected epitopes in HPV-16 and α-7 species, d) Alignment 
of selected epitopes in HPV-16 and α-9 species, e) Alignment of selected epitopes in 
HPV-16 and α-11 species. The locations of MHC (amino acids with numbers 2, 8 and 9), 
are conserved in α-papillomaviridea family. 
Fig. 2 
a) Graphical picture of vaccine structure, the vaccine is consisted of five segments: Two 
epitopes and adjuvants: flagellin (TLR5 agonist), which has two segments: N terminal 
(head) and C-terminal (tail) and RS09 (TLR-4 agonist) and these segments are linked 
together by short linkers. 
b)The refined 3D structure of the designed vaccine. The 3D structure of the designed 
vaccine was suggested through homology modeling by I-Tasser, then the best proposed 
model was refined by GalaxyRefine and display using Pymol software. 
Fig. 3 The result of the structural quality of the vaccine in ERRAT. ERRAT plot showed 
the overall quality factor of the refined structure as 96.617. Good high resolution 
structures usually produce values around 95% or higher. 
Fig.4 Docking model (cartoon representation) of human TLR5 protein in complex with 
the vaccine molecule obtained by Cluspro. TLR5 protein is shown in white. N-terminus 
and C-terminus of flagellin are shown in blue and red, respectively.TLR4 adjuvant is 











of flagellin N and C- terminals and TLR4 are shown in shown in magnify. Docked 
model was visualized via Pymol software. 
Fig. 5 Evaluation of the three important parameters of the codon-optimized gene for high-
level protein expression in E. coli as host. a) CAI of gene sequence is 1. A CAI of > 0.8 
is considered as good for expression in selected host. b) The average GC content of the 
sequence is 59.04%. c) Codon frequency distribution (CFD) value of gene sequence 
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Table 1. Selected epitopes from Epitope prediction servers and IFNepitope, ANTIGENpro, Vaccijen 2.0 and AllergenFP v.1.0 server. The bolded sequences were finally 












Physicochemical properties Value  
Molecular Weight (Da) 29960.11 
Instability index 39.94  Stable 
Gravy -0.470 
Aliphatic index 84.96 
Theoretical pI 7.97 
No. amino acids 278 
Total no. of negatively charged residues 
(Asp+Glu) 
23 
Total no. of positively charged residues 
(Arg+Lys) 
24 
No. of atoms 4178 
Solubility / cclomics 25% 
Solubility / solpro 0.544158 
Antigenicity 
Antigenicity / ANTIGENpro 
 
0.938806 (Antigen) 
Antigenicity /vaxijen 0.4283 ( Probable ANTIGEN ) 
Allergenicity / AllergenFP v.1.0 Probable Non-Allergen 
 
Table 2. Evaluation of physicochemical properties structure, antigenicity and allergencity 
of designed vaccine 
 
 
Outlier region Allowed region Favored region 
1 (0.4%) 6 (2.2%) 272 (97.5%) 
 













Propensity score Contact no. Amino acid No. 
residue 
 
-3.437 -2.844 8 SER 33 1 
-2.374 -2.682 0 ALA 41 2 
-2.962, -3.278 -3.347, -3.444 0.2 ALA, ALA 45, 46 3 
-3.435 -3.491 3 ALA 49 4 
-3.214 -2.592 8 ARG 53 5 





15, 5, 17 ILE, LYS, GLY 58- 60 7 





14, 6, 23 SER, ARG, 
ASN 
65- 67 9 
-1.434, -3.019 -0.581, -0.553 8, 22 ASN, ASP 69, 70 10 
-3.511, -2.304 -1.888, -1.044 16, 12 ILE, SER 72, 73 11 
-1.996, -3.298  -1.216, -0.608 8, 24 GLN, THR 76, 77 12 
-2.382, -1.234 -0.612, 0.034 16, 11 GLU, GLY 79, 80 13 





15, 11, 28 ASN, ASN, 
ASN 
68- 88 15 
-2.289, -2.571 -1.677, -0.697 7, 17 GLN, ARG 90, 91 16 
-1.779 -0.841 9 GLU 94 17 
-1.583, -2.821 -1.009, -1.238 6, 15 ASN, GLY, 
THR 












-3.551, -0.073,  
0.106, -3.405, -
2.495, 0.608, -








3, 1, 0, 12, 21, 
3, 7, 31, 20, 6, 
19, 31, 9, 8, 
27 
SER, ASP, SER, 
ASP, LEU, 




































13, 6, 24, 26, 
8, 9, 30, 5, 24, 


































11, 27, 8, 21, 









-1.626 -1.058 6 THR 157 26 
-3.100 -1.943 12 ASP 159 27 
-1.894, -2.369 -0.841, 0.181 10, 22 SER, ALA 162, 
163 
28 
-3.484, -2.050 -0.948, -0.627 29, 13 PRO, HIS 165, 
166 
29 










-3.344, -1.981 -1.309, -0.939 19, 10 TYR, HIS 181, 
182 
32 
-2.745 -1.672 11 GLY 184 33 
-2.766, -3.204 -2.216, -2.971 7, 5 SER, ARG 186, 
187 
34 











-3.080 -2.181 10 SER 206 36 
-3.255 -2.898 6 TYR 210 37 
-3.168, -3.697 -2.540, -3.008, 8, 9 ARG, GLU 213, 
214 
38 
-3.293 -2.941 6 PHE 217 39 












-1.742, -1.313 -0.799, -0.704 9, 6 GLY, ASN 227, 
228 
42 
-2.326, -2.813 -1.849, -2.139 6, 8 THR, ASN 231, 
232 
43 
-3.605 -2.644 11 ASN 234 44 
-3.129 -3.536 0 ALA 246 45 
-3.585, -3.471 -3.791, -3.272 2, 5 VAL, SER 249, 
250 
46 




Table 4. Conformational B-cell epitopes identified in the refined 3D structure of the designed vaccine using 
Disco Tope 
Jo
ur
na
l P
re
-p
ro
of
